Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Abelzeta Inc. currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio involves 2 distinct examiners and 2 distinct art units. ILIA I OUSPENSKI is the busiest examiner, accounting for 1 pending office action. The 2 pending office actions are distributed across 2 different examination groups, reflecting a decentralized prosecution effort.
The distribution of 2 pending office actions across 2 distinct examiners indicates that the company must manage multiple prosecution timelines. Because ILIA I OUSPENSKI handles 1 pending office action, the workload is split evenly among the assigned staff. This 2 distinct examiners and 2 distinct art units structure requires the company to address different examiner expectations and art unit guidelines within the Biotechnology & Pharmaceuticals field. The presence of 2 pending office actions across 2 distinct art units suggests that the company's current intellectual property covers multiple technical classifications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| FERNANDEZ, SUSAN EMILY | 1 | 52.3% | +60.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044263 | METHODS FOR LYSING BACTERIAL CELLS | FERNANDEZ, SUSAN EMILY | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044263 | METHODS FOR LYSING BACTERIAL CELLS | FERNANDEZ, SUSAN EMILY | 12d |
| 18263050 | CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18263050 | CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 | OUSPENSKI, ILIA I | 1644 | §102§112DP | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18044263 | METHODS FOR LYSING BACTERIAL CELLS | FERNANDEZ, SUSAN EMILY | 1651 | §103§112 | Non-Final OA | 12d | Pending | Mar 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAbelzeta Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Ilia I Ouspenski has the most, with 1 of Abelzeta Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
